Buy Cagrilintide Online
Cagrilintide is a long-acting synthetic amylin analogue peptide developed to reproduce important satiety-related actions of the naturally occurring pancreatic hormone amylin.
It is particularly interesting because it operates through an amylin pathway rather than directly duplicating GLP-1 activity, making it an important peptide for research into appetite and body-weight regulation.
Product Information
Cagrilintide is designed to activate amylin-related pathways involved in satiety, food intake, and gastric emptying.
Its long duration allows it to be investigated as a once-weekly peptide.
How Does Cagrilintide Work?
Cagrilintide mimics key actions of amylin, increasing satiety signaling and influencing gastric emptying and food intake.
Cagrilintide Benefits
Strengthens Satiety Signaling
Amylin is naturally released alongside insulin after meals and plays an important role in signaling fullness. Cagrilintide reproduces this pathway, making it particularly interesting for appetite-regulation research.
Supports Weight-Reduction Research
A Phase 2 dose-finding trial evaluated once-weekly cagrilintide across multiple doses and demonstrated dose-dependent effects on body weight. The highest tested dose, 4.5 mg, produced the greatest weight reduction among the cagrilintide groups.
Provides an Alternative Metabolic Pathway
Unlike GLP-1 peptides, cagrilintide works primarily through amylin-related mechanisms. This gives researchers a separate pathway for studying appetite and energy intake.
Important for Combination-Peptide Research
Cagrilintide has also been studied in combination with semaglutide. Combining amylin and GLP-1 signaling provides a useful model for investigating whether complementary peptide pathways can produce greater metabolic effects than either pathway alone.
Cagrilintide Side Effects
Clinical research has primarily reported nausea, constipation, diarrhea, and vomiting, with gastrointestinal effects generally becoming more prominent as doses increase.
Cagrilintide Dosage
The Phase 2 clinical trial evaluated 0.3, 0.6, 1.2, 2.4, and 4.5 mg once weekly. These were controlled clinical-trial doses.
Research Reference
Lau DCW, Erichsen L, Francisco AM, et al. Once-Weekly Cagrilintide for Weight Management in People with Overweight and Obesity: A Multicentre, Randomised, Double-Blind, Placebo-Controlled and Active-Controlled, Dose-Finding Phase 2 Trial. The Lancet. 2021;398(10317):2160–2172. PMID: 34798060.
PubMed — PMID 34798060
Purerawz Disclaimer
Purerawz does not sell these products. The information provided on this website is intended for educational and informational purposes only. Product information, research findings, reported benefits, dosage information, and side effects are presented to help readers understand the scientific literature surrounding these compounds. Where applicable, clinical-trial doses are reported as study information and should not be interpreted as individualized medical advice.
Purerawz operates as an affiliate-information website and does not manufacture, stock, dispense, or directly sell the products discussed. Readers interested in purchasing a product should use the relevant affiliate links provided on the website and review the supplier’s own product information before making any purchase.
